FDAnews Drug Daily Bulletin

Drug Misbranding Investigations Remain Top Priority: DOJ

Jan. 31, 2013
A U.S. Department of Justice official told pharmaceutical companies and counsel that investigating drug misbranding will remain a major priority for the agency in the upcoming year, maintaining that although courts have determined truthful off-label promotion is protected free speech, there is still underlying conduct to prosecute.